The Nurse View: Top Ten Things to Know About Immune-Mediated Adverse Events.

Slides:



Advertisements
Similar presentations
CCO Independent Conference Highlights
Advertisements

Clinical Application of Immune Checkpoint Inhibitors in Bladder Cancer
Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
CCO Independent Conference Coverage
Immunotherapies: Key Considerations in the Identification and Management of irAEs.
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
Group 6 Melinda Bachini, Thelma Brown, Jean Di Carlo-Wagner, Bob Riter, Chris Kinsinger, Keith Chan, Penny Blaisdell IMMUNOTHERAPY.
IL-12 and IL-23.
New Guidelines to Prevent SCD: What You Need to Know
Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
Optimizing Therapy for Osteoarthritis
Goals of Therapy for Patients With UC
New Therapies for Hyperkalemia Across the Continuum of Care
The Nurse View.
Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Endocrine System.
Introduction to Checkpoint Inhibitors
The Tumor Microenvironment
Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.
The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.
The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.
What Do We Know About LDL-C?
Emerging Data in Cancer Supportive Care
Clinical Considerations in Evidence-based Management of GIST
Emerging Basal Insulins for Diabetes
The Nurse View.
When Would You Use Single Inhaler Triple Therapy in COPD?
Optimizing Management of Advanced Bladder Cancer
Checkpoint Inhibition
Updates in Preventing Skeletal-Related Events in Multiple Myeloma
Checkpoint Inhibition
Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Detecting and Treating Asparaginase-Related Toxicities in Acute Lymphoblastic Leukemia.
Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Skin.
Tackling Atopic Dermatitis
Program Goals Disclaimer Overview Assessing Disease Activity.
Managing Adverse Events With New Oral Therapies in CLL
Optimizing Outcomes and Managing Adverse Events in CLL
Charting Progress in MS Treatment:
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.
Aspirin and Cardioprevention in 2018
US and European Perspectives on Sinusoidal Obstruction Syndrome
Locally Advanced Lung Cancer
I have an increased risk of the following autoimmune adverse events:
Managing Your Patient’s Maintenance Therapy for Multiple Myeloma
Evaluating BTK Inhibitors in CLL
Possible Causes of imAEs
Incorporating Prostacyclins Into Practice
Improving Effective Basal Insulin Use in Clinical Practice
From Adjuvant to Metastatic in Melanoma
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Prioritizing Prevention of HPV-Related Disease
Clinical Considerations in Evidence-based Management of GIST
The Nurse View: Spotlight on EGFR-Mutated NSCLC
A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors
Moving Care Forward in Advanced Gastric Cancer
The Nurse View.
Presentations of thyroid disorders after receiving immune checkpoint inhibition combination therapy or monotherapy. Presentations of thyroid disorders.
Care Team Collaboration for CAR T-Cell Therapy: Real-World Advice
Treatment Initiation and Selection in Newly Diagnosed CLL
Emerging Basal Insulins for Diabetes
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.
Interprofessional Approach to Managing Adverse Events of PI3K Inhibitors.
Presentation transcript:

The Nurse View: Top Ten Things to Know About Immune-Mediated Adverse Events

Immune Checkpoint Inhibition

Incidence of imAEs

Organ Systems Affected by imAEs

Risk for Pneumonitis

Image of Pneumonitis

General Principles of Management for Pneumonitis

Grading Pneumonitis

Management of Grade 1/2 Pneumonitis

Management of Grade 3/4 Pneumonitis

Overview of GI imAEs: Diarrhea vs Colitis

Risk for Diarrhea

Patient Education on Diarrhea and Colitis

General Principles of Management for Diarrhea vs Colitis

Grading Colitis and Diarrhea

Management of Grade 1/2 Colitis

Management of Grade 3/4 Colitis

Overview of Skin imAEs

Types of Skin Toxicities

Image of Dermatitis Rash

Image of Bullous Pemphigoid

Patient Education on Skin Toxicities

Maculopapular Rash/Dermatitis ASCO®/NCCN® Grading System

Management of Grades 1 to 4 Maculopapular Rash/Dermatitis

Rash Induced by Chemoimmunotherapy

Types of Endocrinopathies

Detection of Thyroid Dysfunction

Management of Thyroid Dysfunction

Detecting Hypophysitis and Adrenal Insufficiency

Patient Education on Thyroid Dysfunction

ASCO® Guidelines on Hypothyroidism

Detection and Management of Rare imAEs

Key Takeaways

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.